October 2020—Novodiax released two rapid ihcDirect reagent test kits for in vitro diagnostic use, ihcDirect CK19 and ihcDirect CK20.
IhcDirect CK19 Ab is a polyHRP-conjugated antibody. Staining for CK19 can be seen in normal and malignant tissues, such as breast cancer, endometrial cancer, hepatoid adenocarcinoma, renal carcinoma, urothelial carcinoma, lung cancer, Paget disease, pancreatic ductal carcinoma, squamous cell carcinoma, and thyroid papillary carcinoma.
The ihcDirect CK20 Ab is an epithelial marker. This marker is often performed with other markers such as CK7 to help differentiate types of cancers and has been used in colon, gastric, hepatocellular, ovarian, and prostate cancers.
The ready-to-use antibodies are packaged with color-matched lids and are available in 5-mL, 10-mL, 15-mL, and 30-mL sizes.
The company also released a rapid, 12-minute ihcDirect SOX10 assay for in vitro diagnostic use. IhcDirect SOX10 is a polyHRP-conjugated anti-human rabbit monoclonal antibody (clone R1008) IHC reagent for use on frozen and formalin-fixed, paraffin-embedded sections. Positive nuclear staining for SOX10 is seen in breast basal-like, unclassified triple negative, and metaplastic carcinomas. SOX10 also shows an increased specificity for soft tissue tumors of neural crest origin, when compared with S100.
The ready-to-use antibody is packaged in two different configurations—with ihc Enhancer and antibody only, in 5-mL, 2 × 5-mL, 15-mL, and 2 × 15-mL sizes.
Novodiax, 510-342-3043